Floatz Rating
C39/100
Confidence
Indicative
Sponsor
University of Nebraska
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05220046CT.gov Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Biliary Tract Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Teonanacatl (this asset) | University of Nebraska | P1 | C · 39 |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P3 | BB |
| Epirubicin | Merck Sharp & Dohme LLC | P3 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Fluorouracilum | Shenzhen Xinhe Biomedical | P2 | B |
| Capecitabine | Zhejiang Cancer Hospital | P2 | B |
| S-1 | National Health Research Institutes, Taiwan | P2 | B |
| Durvalumab | Replimune, Inc. | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | AHS Cancer Control Alberta | P2 | B |
+42 more in the Biliary Tract Cancer cohort
Other indications for Teonanacatl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P2 | BB · 68 |
| Major Depressive Disorder | — | P3 | BB · 65 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Teonanacatl in Biliary Tract Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/teonanacatl-biliary-tract-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →